- Brixton Biosciences secures $33M in Series B funding to advance novel technology for pain treatment
- Neural Ice™ technology shows promising results in first-in-man studies
- Capital to be used for pivotal clinical studies in chronic and acute pain indications
- Company aims to expand Neural Ice™ platform to multiple pain indications with long-lasting effects
- Appointment of Dr. Michael Fishman as Chief Medical Officer and Reggie Groves to Board of Directors
Revolutionizing Pain Treatment with Brixton Biosciences’ Neural Ice™ Technology
Pain management is a critical aspect of healthcare, with millions of individuals suffering from chronic and acute pain conditions worldwide. Traditional pain treatments often come with limitations, such as short duration of relief or complex administration processes. However, Brixton Biosciences is changing the game with its innovative Neural Ice™ technology, offering a novel approach to pain relief that could revolutionize the field. Let’s delve into the details of Brixton Biosciences’ recent announcement of $33M in Series B funding and the potential impact of its cutting-edge technology on pain management.
The Breakthrough Neural Ice™ Technology
Brixton Biosciences has been making waves in the life sciences industry with its groundbreaking Neural Ice™ technology. Unlike conventional pain treatments that rely on systemic medications or local anesthetics, Neural Ice™ takes a different route by directly targeting nerves to provide long-lasting pain relief. The simplicity of the treatment lies in its injectable form, offering a familiar and targeted approach to managing pain.
The key to Neural Ice™’s effectiveness lies in its ability to potentially provide pain relief for an extended period of 3-6 months. This is a significant advancement compared to existing treatments that often last for a much shorter duration. By offering a simple and ultra-long acting injectable nerve block, Brixton Biosciences aims to provide patients with a sustainable solution for managing both chronic and acute pain conditions.
Related Video
Advancing Pain Treatment with Series B Funding
The recent announcement of $33M in Series B funding for Brixton Biosciences marks a significant milestone in the company’s journey towards transforming pain management. Led by Schooner Capital and with participation from prominent investors like SV Health Investors and Catalyst Health Ventures, this funding round will enable Brixton to initiate pivotal clinical studies for treating knee pain associated with osteoarthritis and knee replacement surgery.
With the support of this capital infusion, Brixton Biosciences plans to expand the applicability of its Neural Ice™ platform beyond knee-related indications to address a wide range of pain conditions. The company’s vision of offering a simple injectable nerve block that can provide months of relief represents a paradigm shift in the way pain is treated, potentially setting a new standard in pain management.
Driving Innovation in Pain Management
Brixton Biosciences’ commitment to innovation in pain management is further underscored by the appointment of Dr. Michael Fishman as Chief Medical Officer and Reggie Groves to its Board of Directors. Dr. Fishman, a renowned Key Opinion Leader in Pain Management and a double board-certified Anesthesiologist and Pain Medicine specialist, brings a wealth of expertise to the team.
Reggie Groves, an industry veteran with a successful track record at companies like Medtronic, adds a global perspective and diverse skill set to Brixton’s leadership. Her experience in driving sustainable results in medical devices and pharmaceuticals will be instrumental in guiding the company’s expansion strategy and ensuring the success of its innovative pain therapies.
Brixton Biosciences’ Neural Ice™ technology holds immense promise in revolutionizing pain treatment. With the backing of a strong investor consortium, a talented leadership team, and a visionary approach to pain management, Brixton is poised to make a significant impact in improving the quality of life for patients suffering from chronic and acute pain conditions. Stay tuned for more exciting developments from this trailblazing company as they pave the way for a new era in pain relief.
Links to additional Resources: